I-PARTS Integrated Platform for Anti-Cancer Radiation Therapeutics Screening

我们建议开发一个用于癌症药物筛选的高通量克隆细胞存活分析的集成模块。I-Parts，用于抗癌放射治疗药物筛选的集成平台，将细胞培养自动化、微流体和高速图像分析方面的最新进展与高输出X射线照射相结合。在商业上，该产品还具有高通量分析各种不同X射线剂量的抗癌药物和不同细胞系的范围和可行性。允许细胞在具有体内模拟材料的三维环境中生长，进一步促进了iParts模块被应用于患者肿瘤样本克隆生存分析，以预测放射治疗能力。实验验证和商业化将通过第二阶段SBIR提案进行。

We propose to develop an integrated module for high-throughput clonogenic cell survival assay in cancer drug screening. I-PARTS, Integrated platform for anti-cancer radiation therapeutics screening combines the recent advances in cell culture automation, microfluidics, and high-speed image analysis with the highthoughput X-ray irradiation. Commercially, the product also has the scope and feasibility to analyze various cancer drugs with variable X-ray doses, and different cell lines in a high-throughput manner. Allowing the cells to grown in the 3-dimensional environment with in vivo mimicking materials further facilitates the IPARTS module to be adopted in in patient tumor sample clonogenic survival assay predicting radiocurability. Experimental validation and commercialization will be pursued by a phase II SBIR proposal.